The first commercial TIL therapy is brewing at Iovance, along with various clinical readouts which are set to come to fruition in 2023, along with the 5th TIL Therapies Summit which returns as the only forum to address bottlenecks in end-to-end TIL development from discovery now through to commercialization.  

Unite with TIL experts across industry and academia as pioneers from Iovance Biotherapeutics, Turnstone Biologics, Achilles Therapeutics and Lyell Immunopharma share clinical updates, next-gen engineering, and novel innovations to reduce cost and turnaround time to turbocharge preclinical and clinical development of safe, scalable and effective TIL therapies. 

With 23+ TIL expert speakers, 75% of which new, 8 new companies and a brand-new Manufacturing & Characterization Bootcamp, you won’t want to miss this unrivalled opportunity to connect and collaborate with this niche community to secure clinical validation, turbocharge modified therapies and accelerate the next wave of TIL therapies into the clinic and beyond.